bioRxivBiophysicsPreprint
Dual domain recognition determines SARS-CoV-2 PLpro selectivity for human ISG15 and K48-linked di-ubiquitin
P. M. Wydorski, J. Osipiuk, B. T. Lanham, C. Tesar, M. Endres, E. Engle, R. Jedrzejczak, V. Mullapudi, K. MichalskaiD, K. Fidelis, D. Fushman, A. JoachimiakiD, L. A. Joachimiak
Abstract
The Papain-like protease (PLpro) is a domain of a multi-functional, non-structural protein 3 of coronaviruses. PLpro cleaves viral polyproteins and posttranslational conjugates with poly-ubiquitin and protective ISG15, composed of two ubiquitin-like (UBL) domains. Across coronaviruses, PLpro showed divergent selectivity for recognition and cleavage of posttranslational conjugates despite sequence conservation. We show that SARS-CoV-2 PLpro binds human ISG15 and K48-linked di-ubiquitin (K48-Ub2) with nanomolar affinity and detect alternate weaker-binding modes. Crystal structures of untethered PLpro complexes with ISG15 and K48-Ub2 combined with solution NMR and cross-linking mass spectrometry revealed how the two domains of ISG15 or K48-Ub2 are differently utilized in interactions with PLpro. Analysis of protein interface energetics predicted differential binding stabilities of the two UBL/Ub domains that were validated experimentally. We emphasize how substrate recognition can be tuned to cleave specifically ISG15 or K48-Ub2 modifications while retaining capacity to cleave mono-Ub conjugates. These results highlight alternative druggable surfaces that would inhibit PLpro function.
- organism: human
- assay: proteomics
- research focus: host-pathogen & immune response
- approach: experimental assay
Reproducibility ledger
Nobody has reported trying to reproduce this paper yet. Did you replicate an experiment or run the code? Your report saves the next lab a week.
Sign in to file a reproducibility report.
Related papers
- Mechanism and inhibition of SARS-CoV-2 PLpro
T. Klemm, G. Ebert, … D. Komander·bioRxiv·Jun 18, 2020
- Activity profiling and structures of inhibitor-bound SARS-CoV-2-PLpro protease provides a framework for anti-COVID-19 drug design
W. Rut, Z. Lv, … S. K. Olsen·bioRxiv·Apr 29, 2020
- SARS-CoV-2 papain-like protease PLpro in complex with natural compounds reveal allosteric sites for antiviral drug design
V. Srinivasan, H. Brognaro, … P·Communications BiologyPeer-reviewed·Aug 11, 2022
- Structural basis for the inhibition of the papain-like protease of SARS-CoV-2 by small molecules
- SARS-CoV-2 PLpro whole human proteome cleavage prediction and enrichment/depletion analysis
Lucas Prescott·bioRxiv·Oct 4, 2021
- Specificity profiling of SARS-CoV-2 PLpro using proteome-derived libraries of linear peptides suggests secondary preference for basic motifs
Daniel Vogele, Klemens Fröhlich, … Oliver Schilling·Archives of Biochemistry and BiophysicsPeer-reviewed·May 28, 2026